The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO 2019 | FIGHT-202 data: pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma

Name: FIGHT-202 data: pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma
Uploaded: 2019-09-29T00:00:00Z
Duration: 2 min 14 s
Description: Arndt Vogel, MD, PhD, Hannover Medical School, Hannover, Germany, discusses the FIGHT-202 study (EudraCT: 2016-002422-36) of pemigatinib in patients with previously treated locally advanced or metastatic cholangiocarcinoma. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Arndt Vogel • 29 Sep 2019

ESMO 2019

Bile Duct Cancer Gastrointestinal Cancer Pemigatinib

FIGHT-202

Arndt Vogel, MD, PhD, Hannover Medical School, Hannover, Germany, discusses the FIGHT-202 study (EudraCT: 2016-002422-36) of pemigatinib in patients with previously treated locally advanced or metastatic cholangiocarcinoma. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.